The combined clinical and molecular heterogeneity of prostate cancer necessitates the use
of prognostic, predictive, and diagnostic biomarkers to assist the clinician with treatment …

Over the past decade, the detection and analysis of liquid biopsy biomarkers such as
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced …

Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

The therapeutic landscape of castration-resistant prostate cancer (CRPC) has rapidly
expanded. There is a need to develop noninvasive biomarkers to guide treatment. We …

Epigenetic alterations, including changes in DNA methylation, histone modifications and
nucleosome remodeling, result in abnormal gene expression patterns that contribute to …

In recent years, new therapeutic options have become available for prostate cancer (PC)
patients, generating an urgent need for better biomarkers to guide the choice of therapy and …

Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …

Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with
a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also …

We report a new mechanism of androgen receptor (AR) mRNA regulation and cytoprotection
in response to AR pathway inhibition (ARPI) stress in prostate cancer (PCA). AR mRNA …

PURPOSE Despite decreased screening-based detection of clinically insignificant tumors,
most diagnosed prostate cancers are still indolent, indicating a need for better strategies for …